Revel Pharmaceuticals Inc.
Publicly observedSan Francisco, United States
Seen in a public record (e.g. a government grant database); not otherwise verified.
Details and provenance
| Item | Value | Source | Status |
|---|---|---|---|
| Country | US | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| City / locality | San Francisco | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| Name | Revel Pharmaceuticals Inc. | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| UEI (U.S. federal entity ID) | RBFMLGKG8KZ3 | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
Recorded events
- Grant1 Aug 2025Publicly observed
NIH SBIR/STTR award: Development of advanced glycation end product (AGE)-breaking enzymes as a novel therapy for the treatment of diabetic retinopathy
USD 358,065.00 · National Eye Institute · Source: NIH RePORTER (opens in a new tab)
- Grant15 Aug 2023Publicly observed
NIH SBIR/STTR award: Development of enzymatic tools for rapid measurement of Advanced Glycation and Lipoxidation End Product-protein adducts
USD 923,550.00 · National Institute on Aging · Source: NIH RePORTER (opens in a new tab)
- Grant15 Aug 2023Publicly observed
NIH SBIR/STTR award: Development of enzymatic tools for rapid measurement of Advanced Glycation and Lipoxidation End Product-protein adducts
USD 1,364,162.00 · National Institute on Aging · Source: NIH RePORTER (opens in a new tab)
Information only — not investment advice or an endorsement. Is this your company? Submit or update its details or request a correction.